Providers across specialties are challenged as to how and when to implement the plethora of guideline recommendations (ACC, ADA, AHA, KDIGO, ESC) in practice. Our experts review clinical trial evidence on SGLT2 inhibitors using different patient case vignettes to increase the relevance of their message. Tune in to see how SGLT2 inhibitors can improve outcomes beyond glycemic control so you can develop individualized strategies to escape the treatment trap.
Cardiorenal Collaboration: Escape the Treatment Trap
Media formats available:
Details
Comments
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Reviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Kathleen Sheridan, PhD, has nothing to disclose.
- Raymond R. Townsend, MD, has nothing to disclose.
- Michael A. Weber, MD, has received consulting fees from Alnylam and Idorsia.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Examine the clinical traits of chronic kidney disease (CKD) for prompt diagnosis and treatment initiation
- Assess the real-world implications of recent clinical trial findings on SGLT-2 inhibitors for disease progression in a diverse patient population with CKD and/or heart failure (HF)
- Incorporate the ADA-KDIGO consensus recommendations along with other guidelines such as ESC-HF, ADA, and AHA in designing treatment protocols for patients suffering from CKD and/or HF, irrespective of their diabetes status
- Develop strategies for using SGLT-2 inhibitors in patients with and without diabetes to improve cardiorenal outcomes
- Apply approaches to coordinated interdisciplinary care for cardiorenal metabolic patients throughout the system from a center of excellence
Target Audience
This activity is designed to meet the educational needs of primary care physicians, cardiologists, nephrologists, endocrinologists, and hospitalists, as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with cardiorenal metabolic disease.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until December 04, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour/0.1 CEUs of pharmacy contact hours.
The Universal Activity Number for this program is UAN JA0006235-0000-24-129-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).Provider(s)/Educational Partner(s)
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.Commercial Support
This activity is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc., and Eli Lilly and Company.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- CME/CE
The Shifting ATTR-CM Landscape: Early Diagnosis, Emerging Therapies & Personalized Care
0.50 credits
Pablo Garcia-Pavia, MD, PhD
Francesco Cappelli, MD
Jörg Latus, MD
Sydney Tang, MBBS, MD
James Burton, DM, FRCP
Carol Pollock, AO, MBBS, PhD, FRACP, FAHMS
- CME/CE
Optimizing Outcomes in Patients With IgAN: Novel Therapies and Evolving Guidelines
0.25 creditsJürgen Floege, MD
Jonathan Barratt, PhD
